List of Piqray drug patents
Piqray is owned by Novartis.
Piqray contains Alpelisib.
Piqray has a total of 2 drug patents out of which 0 drug patents have expired.
Piqray was authorised for market use on 24 May, 2019.
Piqray is available in tablet;oral dosage forms.
Piqray can be used as in combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer.
Drug patent challenges can be filed against Piqray from 2023-05-25.
The generics of Piqray are possible to be released after 28 September, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 2023-05-25
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
PIQRAY family patents
5
United States
3
European Union
2
Cyprus
2
Argentina
2
Hungary
1
Colombia
1
Ecuador
1
Panama
1
Australia
1
EA
1
El Salvador
1
Israel
1
Croatia
1
Dominican Republic
1
Korea, Republic of
1
Netherlands
1
Canada
1
New Zealand
1
Denmark
1
Honduras
1
Spain
1
Tunisia
1
Uruguay
1
Peru
1
Malaysia
1
Costa Rica
1
Nicaragua
1
Chile
1
ME
1
Jordan
1
Portugal
1
Ukraine
1
Poland
1
Japan
1
Morocco
1
Norway
1
Hong Kong
1
Slovenia
1
San Marino
1
Mexico
1
Brazil
1
Cuba
1
South Africa
1
RS
1
China
1
Georgia
1
Taiwan
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic